Skip to main content
. 2018 Feb 11;20(3):233–243. doi: 10.1016/j.neo.2018.01.006

Figure 4.

Figure 4

Dasatinib inhibits paracrine FGF10-induced prostate tumorigenesis. Epithelial cells were mixed with GFP- or FGF10-UGSM. The cell mixture was implanted under the kidney capsule of SCID mice. After 4 weeks of incubation, host mice carrying the regenerated grafts were treated with dasatinib by gavage (75 mg/kg). The regenerated prostate tissues were harvested for pathological analysis after 4 weeks of treatment and analyzed for H&E staining, IHC staining of CK5 (red)/CK8 (green)/DAPI (blue) and E-Cadherin (red)/vimentin (green)/DAPI (blue). The 1:1 ratio of epithelial cells to FGF10-UGSM resulted in branched tubules, and the 1:2 ratio led to adenocarcinoma. Pathological analysis indicated that dasatinib inhibits paracrine FGF10 induced tumorigenesis. Scale bar, 100 μm.